Ki67 protein: the immaculate deception?

Brown, D. C.; Gatter, Kevin C.

doi:10.1046/j.1365-2559.2002.01343.x

Cited by 465 publications

(393 citation statements)

References 125 publications

Supporting

Mentioning

354

Contrasting

Unclassified

Order By: Relevance

“…Some studies used cell proliferation markers to estimate the prognosis and outcome of salivary gland tumors. Ki-67 is the most commonly applied proliferation marker which has been used to study of several human malignancies such as soft tissue sarcoma, meningioma, breast cancer and nonHodgkin's lymphoma (Brown and Gatter, 2002;Pich et al, 2004;Van Diest et al, 2004). Ki-67 is present in the nuclei of cells in the G1, S and G2 phases of the cell cycle of dividing cells, as well as in mitosis.…”

Section: Introductionmentioning

confidence: 99%

MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

Jaafari‐Ashkavandi¹,

Najvani²,

Tadbir³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

Jaafari‐Ashkavandi¹,

Najvani²,

Tadbir³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…High proliferation rates have been shown to be associated with worse prognosis in breast cancer, and also with a higher probability of response to chemotherapy. 1,[3][4][5][6][7][8] Proliferation can be measured by thymidine labeling index and flow cytometric analysis of S-phase fraction. These two markers have been evaluated in prospective trials, 9,10 but the complexity of the assays and the need for fresh frozen tumor tissue have limited their use.…”

mentioning

confidence: 99%

“…5,8,[17][18][19][20][21][22] It is also a predictor of better response to chemotherapy. 5,7 Furthermore, as Ki67 is also affordable and easily assessed on paraffin-embedded tumor material, it has been widely used, even though it has not been generally recommended for use by all guidelines, 1,2 as there is no international standardization for the method.…”

mentioning

confidence: 99%

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to evaluate the prognostic value of Ki67 in relation to established prognostic factors in lymph node-negative breast cancer, and furthermore, whether the prognostic impact was dependent on estrogen receptor (ER) status and histological grade. In 200 premenopausal patients, with 5 years of follow-up, Ki67 was determined on tissue microarrays. In univariate analysis, Ki67 (r20 vs 420%) was a prognostic factor for distant disease-free survival (hazard ratio: 2.7, 95% confidence interval: 1.3-5.4, P ¼ 0.005) and overall survival (hazard ratio: 4.9, 95% confidence interval: 1.7-14, P ¼ 0.003). When stratifying for ER status and histological grade, Ki67 was a significant prognostic factor for distant disease-free survival and overall survival only in the ER-positive group, and only in patients with histological grade 2, respectively. In multivariate analysis, human epidermal growth factor receptor 2 and age were independent prognostic factors for distant disease-free survival, whereas Ki67, histological grade, and tumor size were not. Ki67 was, however, an independent prognostic factor in the 87% of the patients who had not received adjuvant medical treatment. Agreement between the three readers was very good (j-values: 0.83-0.88). Furthermore, Ki67 was a significant prognostic factor for all three investigators (hazard ratio: 2.7-3.2). This study shows that Ki67 is a prognostic factor in node-negative breast cancer. It is noteworthy that the prognostic information of Ki67 is restricted to ER-positive patients, and to patients with histological grade 2. Taken together, Ki67, as an easily assessed and reproducible proliferation factor, may be an alternative or complement to histological grade as a prognostic tool and for selection of adjuvant treatment.

show abstract

“…A histological marker of Ki67/MIB1 labeling index (Ki67/MIB1LI) has been widely validated as a prognostic marker in various tumors [10,11], and demonstrated to be effective in differentiating ACC from adrenal adenomas [8,[12][13][14][15][16][17]. Its prognostic value to predict clinical outcome of ACC is, however, yet to be determined.…”

mentioning

confidence: 99%

Immunohistochemistry of a Proliferation Marker Ki67/MIB1 in Adrenocortical Carcinomas: Ki67/MIB1 Labeling Index Is a Predictor for Recurrence of Adrenocortical Carcinomas

et al. 2008

View full text Add to dashboard Cite

Abstract. Adrenocortical carcinoma (ACC) is a rare, highly malignant tumor. The aim of the present study is to evaluate the prognostic relevance of a proliferation marker Ki67/MIB1 by immunohistochemistry in 17 cases who underwent resections of the primary tumors and diagnosed to have ACC at Tohoku University Hospital based on the criteria of Weiss during the period from 1976 to 2005. The follow-up periods ranged from 221 days to 10659 days (about 29 years) with the median of 1895 days. The median age at diagnosis was 46 years old, and the mean size of the primary tumors was 7.1 cm with the minimal of 3.5 cm. Ki67/MIB1 labeling index (Ki67/MIB1LI) ranged from 1% to 26%. Kaplan-Meier analysis revealed that patients with Ki67/MIB1LI of 7% or more were associated with significantly shortened disease-free survival (P = 0.0037). The evaluation with Weiss criteria revealed that the median score of Weiss criteria was five, and 13 patients (76.5%) presented positive findings in the criteria of mitotic rate. The survival analysis with Weiss score showed that patients with the scores of 6 or more had both significantly shortened disease-free survival (P = 0.0001) and overall survival (P = 0.0063). The present study has suggested that Ki67/MIB1LI, as well as Weiss score, is a useful predictor for tumor recurrence after resection of the primary tumors in patients with ACC.

show abstract

Ki67 protein: the immaculate deception?

Cited by 465 publications

References 125 publications

MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

Immunohistochemistry of a Proliferation Marker Ki67/MIB1 in Adrenocortical Carcinomas: Ki67/MIB1 Labeling Index Is a Predictor for Recurrence of Adrenocortical Carcinomas

Contact Info

Product

Resources

About